|
| miR | Cancer type (effect of expression on treatment) | Treatments investigated |
|
| let-7a | Leukemia [67] (sensitive), breast [68, 69] (sensitive), pancreatic [70] (sensitive) | Ara-C, irradiation, paclitaxel, gemcitabine |
| let-7b | Glioblastoma [71] (sensitive) | Cisplatin |
| let-7c | Esophageal [72] (sensitive) | Cisplatin |
| let-7e | Ovarian [73] (sensitive) | Cisplatin |
| miR-9 | Glioblastoma [74] (resistant) | Temozolomide |
| miR-10b | Colon [75] (resistant) | Fluorouracil |
| miR-15b | Tongue [76] (sensitive) | Gemcitabine |
| miR-17-5p | Pancreatic [77] (resistant) | Gemcitabine |
| miR-19a | Breast [6] (resistant) | Taxol, mitoxantrone, etoposide |
| miR-21 | Gastric [7] (resistant), pancreatic [78–80] (resistant), glioblastoma [81–84] (resistant), colorectal [85, 86] (resistant), adenocarcinoma [87] (resistant) | Gemcitabine, fluorouracil, temozolomide, irradiation, cisplatin |
| miR-23b | Pancreatic [88] (sensitive) | Irradiation |
| miR-29c | Nasopharynx [89] (sensitive) | Cisplatin, irradiation |
| miR-30c | Breast [90] (sensitive) | Paclitaxel, doxorubicin |
| miR-30d, miR-181a and miR-199a-5p | Colorectal, prostate, and leukemia [91] (sensitive) | Trichostatin A |
| miR-31 | Ovarian [92] (sensitive) | Paclitaxel |
| miR-34a | Breast [93] (sensitive), prostate [94] (sensitive), gastric [95] (miR-34c-5p, sensitive) | Adriamycin, camptothecin, paclitaxel |
| miR-92b | Lung [9] (resistant) | Cisplatin |
| miR-93 | Ovarian [5] (resistant) | Cisplatin |
| miR-103 and miR-107 | Osteosarcoma, cervical, lung [96] (sensitive) | AZD2281, cisplatin, etoposide, camptothecin, irradiation |
| miR-106a | Ovarian [97, 98] (sensitive or resistant) | Cisplatin, paclitaxel |
| miR-125b | Breast [99–101] (resistant), Ewing sarcoma [102] (sensitive) | Paclitaxel, fluorouracil, doxorubicin, gemcitabine |
| miR-128-2 | Lung [103] (resistant) | Cisplatin, doxorubicin, fluorouracil |
| miR-130a | Liver [104] (resistant) | Cisplatin |
| miR-140 | Osteosarcoma and colon [105] (resistant) | Fluorouracil |
| miR-141 | Ovarian [106] (resistant) | Cisplatin |
| miR-143 and miR-145 | Colon [107] (sensitive) | Fluorouracil, irinotecan, oxaliplatin |
| miR-145 | Glioblastoma [108] (sensitive), cervical [109] (sensitive) | Irradiation, temozolomide, mitomycin |
| miR-152 and miR-185 | Ovarian [110] (sensitive) | Cisplatin |
| miR-181b | Pancreatic [111, 112] (sensitive or resistant), glioblastoma [113] (sensitive) | Gemcitabine, temozolomide |
| miR-182 | Ovarian [114] (resistant) | Paclitaxel, cisplatin |
| miR-199a-5p | Liver [115] (sensitive) | Cisplatin |
| miR-200b | Pancreatic [80] (sensitive), tongue [75] (sensitive) | Gemcitabine, cisplatin |
| miR-200c | Pancreatic [80] (sensitive), breast [116] (sensitive), ovarian [117] (sensitive) | Gemcitabine, paclitaxel, doxorubicin |
| miR-223 | Liver [118] (sensitive) | Doxorubicin, paclitaxel |
| miR-298 | Breast [119] (sensitive) | Doxorubicin |
| miR-302 | Breast [120] (sensitive) | Irradiation |
| miR-320 | Prostate [121] (sensitive), pancreatic [122] (miR-320c, resistant) | Cisplatin, carboplatin, paclitaxel, gemcitabine |
| miR-375 | Gastric [11] (resistant), cervical [123] (resistant) | Irradiation, etoposide, paclitaxel |
| miR-591 | Ovarian [97] (sensitive) | Paclitaxel |
| miR-650 | Lung [124] (resistant) | Docetaxel |
| miR-663 | Breast [125] (resistant) | Adriamycin, chlorophosphamide, docetaxel |
| miR-708 | Ewing sarcoma [126] (sensitive) | Etoposide, doxorubicin |
|
